| Literature DB >> 24394201 |
D S L Toh1, L L Tan1, D C W Aw2, S M Pang3, S H Lim4, T Thirumoorthy3, H Y Lee3, Y K Tay5, S K Tan6, A Vasudevan7, A Lateef8, Y Y Chong9, Y C Chan10, C Loke1, C L Chan1, E S C Koay11, E C Ren12, E J D Lee13, C Sung14.
Abstract
To study the possible genetic associations with adverse drug reactions (ADR), the Singapore Health Sciences Authority (HSA) has piloted a program to collect DNA and phenotype data of ADR cases as part of its pharmacovigilance program. Between 2009 and 2012, HSA screened 158 cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). To assess the association between HLA-B*1502 and carbamazepine (CBZ)-induced SJS/TEN, 13 cases and 26 drug-tolerant controls were analyzed. All 13 CBZ-SJS/TEN cases and 3/26 controls were HLA-B*1502 positive (odds ratio 181, 95% confidence interval: 8.7-3785, P=6.9 × 10(-8)). Discussions of the finding with the Ministry of Health and an expert panel led to the decision to make HLA-B*1502 testing the standard of care prior to first use of CBZ in Asians and to subsidize the genotyping test at public hospitals. This program illustrates the role of a regulatory authority in advancing the use of pharmacogenetics for drug safety.Entities:
Mesh：
Substances：
Year: 2014 PMID： 24394201 DOI： 10.1038/tpj.2013.46
Source DB: PubMed Journal: Pharmacogenomics J ISSN： 1470-269X Impact factor: 3.550